注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Fate Therapeutics Inc是一家临床阶段的生物制药公司。该公司专注于为癌症患者开发程序化细胞免疫疗法。该公司使用从其专有的iPSC产品平台产生的人类诱导多能干细胞(iPSCs)来创建具有首选生物学特性的基因工程克隆主iPSC系。该公司正在推进一系列程序化细胞免疫疗法,包括来自克隆主iPSC线的现成自然杀伤细胞(NK)和T细胞候选产品,用于治疗癌症。该公司的产品管线包括FT596、FT538、FT576、FT536、FT573、FT819、FT500、FT516。FT516是一种研究性现成的NK细胞癌免疫疗法,源自克隆主iPSC线,被设计用于表达新的CD16(hnCD16)Fc受体。FT596是一种研究性现成的CAR NK细胞癌免疫疗法,源自克隆主iPSC线。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
J. Scott Wolchko | 52 | 2013 | Founder, CEO, President & Director |
John D. Mendlein | 62 | 2007 | Independent Vice Chairman of the Board |
William H. Rastetter | 74 | 2011 | Independent Chairman |
Robert S. Epstein | 67 | 2014 | Independent Director |
Timothy P. Coughlin | 55 | 2013 | Independent Director |
Robert M. Hershberg | 60 | 2020 | Independent Director |
Shefali Agarwal | 48 | 2019 | Independent Director |
Yuan Xu | 53 | 2021 | Independent Director |
Sean J. Morrison | - | 2010 | Member of Scientific Advisory Board |
Lynn Megeney | - | 2010 | Member of Scientific Advisory Board |
Robert S. Langer | 74 | - | Member of Scientific Advisory Board |
Sui Huang | - | 2010 | Member of Scientific Advisory Board |
Stuart Orkin | - | 2010 | Member of Scientific Advisory Board |
Bennett M. Shapiro | 83 | - | Member of Scientific Advisory Board |
Mark Krasnow | - | 2010 | Member of Scientific Advisory Board |
Karin Jooss | 58 | 2019 | Independent Director |
Alberto Hayek | - | 2010 | Member of Scientific Advisory Board |
Steven L. Goldstein | - | 2010 | Member of Scientific Advisory Board |
Michael Stewart Lee | 44 | 2018 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核